Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

The healthcare industry has struggled to keep pace with rapid technological advancements. Zealthy, a telehealth platform, is ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...